AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03725930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: clonidine intranasal premedication in preschool infants
Study NCT03725930 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal premedication
Study NCT01472328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HBO therapy
Description: Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
Study NCT03585699 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT guided Spinal Biopsy
Description: Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis.
Study NCT01658462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 IV Day 1 / 3 weeks
Study NCT01658462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 IV Day 1 / 3 weeks
Study NCT01658462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: 200 mg x 2 per os daily from D2\*~\*No Nintedanib on days when docetaxel is administered
Study NCT01658462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel: increase of the dose
Description: Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
Study NCT01776892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collegenase injection
Description: Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
Study NCT01776892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collegenase injection
Description: Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
Study NCT01776892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle aponeurotomy
Description: Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
Study NCT01776892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle aponeurotomy
Description: Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
Study NCT03570073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual vitrification
Description: Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
Study NCT00967733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed oil-Olive oil
Description: 2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
Study NCT00967733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil-olive oil
Description: 1 gr olive oil pill and olive oil used for cooking
Study NCT00967733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed oil-sunflower oil
Description: 2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
Study NCT00967733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil-sunflower oil
Description: 1 gr olive oil pill and sunflower oil used for cooking
Study NCT01769469 — intervention group
Intervention type: DRUG
Intervention: FTC/TDF (Truvada®)
Description: There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
Study NCT00546286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dorzolamide hydrochloride (+) timolol maleate
Description: Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks.
Study NCT00546286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: dorzolamide HCl/timolol maleate + prostaglandin
Description: Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks.
Study NCT01760759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cell phone reminders
Description: Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
Study NCT01760759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management for adherence
Description: Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
Study NCT02615067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MIP-1404 Injection
Description: A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.
Study NCT02615067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-Body Planar and pelvic SPECT/CT scan
Description: A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404.
Study NCT04462536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle only
Study NCT04462536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerinetide
Description: Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
Study NCT01090219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two different meshes in the repair of inguinal hernias
Description: A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
Study NCT04469816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up 4 Health
Description: A parent-training intervention to improve child health, school readiness and manage obesity.
Study NCT04469816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Services as Usual
Description: Services/Treatment as usual.
Study NCT02437487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-109
Description: SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
Study NCT02437487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
Study NCT02409056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace-tailored CDSMP
Description: This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
Study NCT01732536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
Study NCT01231789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
Study NCT02409056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Self-Management Program
Description: This is the standard CDSMP which has been implemented in community settings.
Study NCT00651612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
Description: Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
Study NCT00651612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent brimonidine 0.2% and 0.5% timolol
Description: Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
Study NCT00505752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS900672-Enriched 50 microgram (mcg)
Description: Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
Study NCT00505752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS900672-Enriched 100 mcg
Description: Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
Study NCT03433690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: High Intensity Interval Training for twelve weeks
Study NCT03433690 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate training
Description: Moderate training for twelve weeks
Study NCT00505752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS900672-Enriched 150 mcg
Description: Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
Study NCT00505752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa 150 international unit (IU)
Description: Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
Study NCT01231789 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham RIPC
Description: Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
Study NCT00937495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: 400 mg given PO
Study NCT01472328 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric room air
Description: Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
Study NCT00735917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given PO
Study NCT00735917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Optional correlative studies
Study NCT00735917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies
Study NCT00735917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Optional correlative studies
Study NCT00548418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study NCT00735917 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Optional correlative studies
Study NCT00937495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^2 given IV
Study NCT04587037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fascia lata allograft
Description: underwent superior capsule reconstruction using fascia lata allograft
Study NCT04587037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human dermal allograft
Description: underwent superior capsule reconstruction using human dermal allograft
Study NCT03667404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin
Description: Resistant maltodextrin powder
Study NCT03667404 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: maltodextrin powder
Study NCT02135744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bundle tool
Description: Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
Study NCT02718235 — intervention group
Intervention type: OTHER
Intervention: Overall survival
Description: Observation of overall and disease free survival
Study NCT02863393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercise
Description: Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
Study NCT03908203 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally invasive one-level lumbar deformity correction
Description: The study treatment represents modified technique of MIS TLIF: one level screws fixation using Wiltse approach at one side, the other side - percutaneously, one level decompression, correction of segmental deformity by performing vertebrotomy and then intervertebral fusion.
Study NCT02886650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermocoagulation
Description: Thermocoagulation During pre-surgical Invasive EEG Monitoring
Study NCT01332214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2820
Description: Subcutaneous Injection in abdomen or Thigh
Study NCT01332214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection in abdomen or Thigh
Study NCT03570073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitrification with GaviTM system
Description: Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
Study NCT01393496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: red blood cell transfusion
Description: Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants
Study NCT01393496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: red blood cell transfusion
Description: Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants
Study NCT03368794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active treatment referral of opioid overdose survivors to long-term treatment
Description: Telephone alert and outreach for inclusion, assessment and intake into long-term evidence-based treatment of the substance use disorder.
Study NCT03368794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Written information from ambulance staff to the patient about how to seek treatment. Patient is able to contact the research treatment facility through a specific phone number, making it possible to study treatment entry in the information-only control condition.
Study NCT06495827 — intervention group
Intervention type: OTHER
Intervention: No different intenvention
Description: No different intenvention
Study NCT00548418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00548418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT05951140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usage of the PROTEIN-Application
Description: Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
Study NCT04248998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet
Description: Cyclic, 5-day, calorie-restricted (600 KCal on day 1; 300 KCal on days 2-5), low-carbohydrate, low protein diet every three weeks
Study NCT04248998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg twice a day
Study NCT00735917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT01338649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright Light Treatment (Sun Ray Sunbox SB-558)
Description: Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
Study NCT01338649 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dim red light (Sun Ray Sunbox SB-558)
Description: Dim red light box administered during two 1 hour periods during the day using
Study NCT00704730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
Study NCT00704730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules color and size-matched to XL184 capsules administered orally daily
Study NCT01296659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
Study NCT04673513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: In light of COVID-19 considerations, interventions are currently being provided via telehealth technology.
Study NCT05906420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ASTRAL prognostic score
Description: ASTRAL prognostic score
Study NCT01679106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAP catheter with Ropivicaine
Description: Patients will receive TAP catheter with continuous infusion of Ropivicaine.
Study NCT01679106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl IV PCA and placebo TAP catheter
Description: Patients will receive placebo TAP catheter with Fentanyl IV PCA.
Study NCT00505752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa 150 international unit (IU)
Description: Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
Study NCT00505752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to \[>=\] 18 millimeter \[mm\], two or more additional follicles with a diameter of >= 16 mm, and Estradiol \[E2\] levels will approximately 150 picogram per milliliter \[pg/mL\] per mature follicle).